Bull, Bear & Beyond – Percheron Therapeutics: executive interview

In this interview, Percheron Therapeutics CEO Dr James Garner discusses the company’s recent pivot to immuno-oncology and the rationale for licensing HMBD-002 as its lead programme. He outlines the potential of HMBD-002 as a novel VISTA-targeting checkpoint inhibitor, its differentiated positioning and the positive preclinical and clinical data reported to date. Dr Garner provides further insight into the ongoing preparatory work for the upcoming Phase II trials in 2026. He also discusses the company’s strategic approach to financing the upcoming studies, and development plans beyond Phase II.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.